Category: Professional Posters
Purpose: Guselkumab, a selective interleukin 23 (IL-23) inhibitor, is indicated for the treatment of moderate-to-severe psoriasis in Taiwan. Guselkumab has established the improvement of Psoriasis Area Severity Index (PASI) Score in many clinical trials. However, effectiveness of guselkumab in Asia population in the real-world clinical practice remains unclear. To fill this gap, the purpose of our study is to analyze prescription pattern and effectiveness of guselkumab.
Methods: This was a retrospective chart review study by using single medical center hospital Electronic Medical Record (EMR) in Taiwan. We included newly used guselkumab psoriasis patients between November 2018 and April 2019, the patients without baseline PASI were excluded. We followed these patients from the initiations of guselkumab to loss of follow-up or May 2019. We performed medical chart reviews to calculate PASI score after 1-month therapy. We also described the patients’ baseline characteristic included sex, age, combination of conventional Disease-modifying anti-rheumatic drugs (DMARDs), previous treatment (biological agents and oral DMARDs), having health insurance or not. Descriptive statistics were used to characterize the information collected.
Results: We included 20 guselkumab users with the mean age of 49 years (SD 12) and 80% of men in our study. Only one patient lost of follow up during study period. The average of PASI score before using guselkumab was 15.32 (SD 7.84), and the average PASI score after using guselkumab for one to three month was 8.40 (SD 7.18). After calculated, the mean delta PASI was 48.8% (SD 26.67). There were 4 (20%) patients reached ∆PASI 75 (≥ 75% improvement from baseline PASI). Prior to initiation of guselkumab, 12 (60%) patients had received other kinds of biological agents (etanercept: 2; ustekinumab: 9; secukinumab: 4; Ixekizumab: 1; Golimumab: 1) and 18 (90%) patients had used DMARDs before. On other hand, there are 6 of them use of conventional DMARDs concomitantly with guselkumab (MTX: 3; acitretin: 2; cyclosporin: 1).
Conclusion: For the use of guselkumab in the management of plaque psoriasis, most of the patients exhibited high level of clinical response. Our findings could serve as a clinical reference for guselkumab to improve plaque psoriasis. On account of our patients using the drug in the short term, there is no relevant information about long-term safety issues. The more real-world evidence must be determined in larger, long-term studies.